Selective Antimicrobial Compounds That Spare Commensal Microbes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antimicrobial compounds are often broad-spectrum, affecting both pathogenic and commensal microbes, leading to increased resistance and undesirable side effects, necessitating higher doses and environmental toxicity.
Innovation Solution
Development of selective antimicrobial compounds, such as those with structures defined by Formulae 1A, 1B, or 1C, that preferentially target and inhibit pathogenic microbes like bacteria, viruses, and fungi while minimizing impact on commensal microbes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum antimicrobial compounds are used to treat infections, then pathogenic microbes are inhibited, but commensal microbes are also inhibited leading to increased resistance and side effects
Solution Approach 1:
The patent applies local quality by designing antimicrobial compounds with specific molecular structures (Formulae 1A, 1B, 1C) that possess selective properties. These compounds have particular functional groups and structural features that enable them to interact preferentially with pathogenic microbes through specific molecular recognition mechanisms, while leaving commensal microbes unaffected. The selective toxicity arises from the localized chemical characteristics of the compound structure that match specific targets in pathogenic but not commensal organisms.
2Reliability
If higher doses of antimicrobial treatments are used to overcome resistance, then efficacy is improved, but toxicity to animals and environment increases
Solution Approach 1:
The patent applies parameter changes by modifying key molecular parameters of antimicrobial compounds, specifically the structural parameters represented by various substituents in Formulae 1A, 1B, and 1C. By systematically varying parameters such as the nature of R1-R6 groups, the type of heteroatoms (X, Y, Z), and the overall molecular architecture, the invention creates compounds with optimized potency and selectivity profiles. This allows achieving high efficacy at lower doses, thereby reducing toxicity.
3Ease of operation
If standard antimicrobial courses are used, then treatment is simple, but resistance develops rendering treatment ineffective
Solution Approach 1:
The patent applies preliminary action by developing and preparing selective antimicrobial compounds in advance with proven efficacy against resistant pathogens. These compounds are designed beforehand with specific structural features that predict their ability to overcome resistance mechanisms. By having these pre-developed selective agents ready, the treatment protocol remains simple (single agent administration) while ensuring effectiveness against resistant strains through the inherent properties of the compounds.
Data Source
AI summary
A method of selectively inhibiting pathogenic microbes includes: providing an antimicrobial compound that is functional having a structure of Formula 1, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof; and contacting a microbe with the compound such that the microbe is selectively inhibited;